David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn:
“Unprecedented advance with Osi+CTx (FLAURA2 trial):
- Uniquely tolerable profile
- Toxicity decreases over time
- Remarkable mDoT of 30.5 mo with Osi That’s 3x longer than Pem to a substantial chemotherapy-free period for our patients EGFRm.”
More posts featuring D. Planchard on OncoDaily.
